How to Cite
Abstract
Despite our successes in understanding of nature appearance of oral mucositis, it still is serious problem for patients that are given antitumor treatment due to local – advanced head and neck cancer. Dangerous of oral mucositis` related with antitumor treatment in that patients consist of decrease quality of patients` life and increase risk of life-threatening complications. We were tasked to estimate of efficacy and feasibility of offered in the world now treatment methods for oral mucositis related antitumor treatment for cancer of head and neck and reflect modern condition of this problem. We used systems of medical date ScopusGoogle Scholar, PubMed and studied modern findings about factors of appearance and flowing this pathological condition in patients that are given of antitumor treatment and also were studied possible ways for prevention and management in oral mucositis. Now there are exist many different types of prevention and treatment of oral mucositis and they all are described in this article. In some cases, use of this methods of management allow to reach decrease of risk of life-threatening complications and increase of life patients` quality but a lot of them are symptomatic, palliative. It makes look for novel therapeutic strategies for management for that patients. For making decisions about intervention, we have to estimate step of hard of that condition in patients which influence to ability to speak and intake of meal per month in patients. All actions are directed to increase of tolerable antitumor treatment, decrease of risks related with this treatment.
References
Elting LS, Cooksley CD, Chambers MS, Garden AS. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies // J RadiatOncolBiol Phys. 2007;68:1110-1120. https://doi:10.1016/j.ijrobp.2007.01.053
Sonis ST. Oral mucositis in head and neck cancer: risk, biology, and management // Am SocClinOncolEduc Book. 2013;3:e236-e240. https://doi:10.1200/EdBook_AM.2013.33.e236
Sonis ST. Oral mucositis Anticancer Drugs. 2011;22:607-612. https://doi:10.1097/CAD.0b013e3283462086
Raber-Durlacher JE, Elad S, Barasch A. Oral mucositis // Oral Oncol. 2010;46:452-456. https://doi:10.1016/j.oraloncology.2010.03.012
Cinausero M, Aprile G, Ermacora P et al. New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury // Front Pharmacol. 2017;8:262-316. https://doi:10.3389/fphar.2017.00354
Lockhart PB, Sonis ST. Alterations in the oral mucosa caused by chemotherapeutic agents. A histologic study // J DermatolSurgOncol. 1981;7:1019-1025. https://doi:10.1111/j.1524-4725.1981.tb00208.x
Al-Ansari S, Zecha JAEM, Barasch A et al. Oral mucositis induced by anticancer therapies // Curr Oral Health Rep. 2015;2:202-211. https://doi:10.1007/s40496-015-0069-4
Elting LS, Keefe DM, Sonis ST et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy // Cancer. 2008;113:2704-2713. https://doi:10.1002/cncr.23898
Bensinger W. NCCN Task Force Report prevention and management of mucositis in cancer care // Natl Compr Canc Netw. 2008;6(1):22-421.
Campos MI, Campos CN, Aarestrup FM, Aarestrup BJ. Oral mucositis in cancer treatment: natural history, prevention and treatment // Mol Clin Oncol. 2014;2:337-402. https://doi:10.3892/mco.2014.253
Galloway T, Amdur R, Posner M et al. Management and prevention of complications during treatment of head and neck cancer // Up To Date, Waltham, MA. 2014;64:12.
Rosenthal DI, Trotti A. Strategies for managing radiation-induced mucositis in head and neck cancer // Semin Radiate Oncol. 2009;19:29-34. https://doi:10.1016/j.semradonc.2008.09.006
Mortensen HR. Factors associated with acute and late dysphagia in the DAHANCA 6&7 randomized trial with accelerated radiotherapy for head and neck cancer // Acta Oncol. 2013;52:1535-1542. https://doi:10.3109/0284186X.2013.824609
Vera-Llonch M. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma // Cancer. 2006;106:329-362. https://doi:10.1002/cncr.21622
Геворков А.Р. Основные принципы ведения пациентов с мукозитом и дерматитом при лучевом лечении с лекарственной модификацией больных плоскоклеточным раком орофарингеальной области // Опухоли головы и шеи. 2016(3):12-21. https://doi:10.17 650/2222-1468-2016-6-3-12-21
Sonis ST The pathobiology of mucositis // Nat Rev Cancer. 2004;4:277-284. 10.1038/nrc1318 https://doi:10.1038/nrc1318
ST Sonis New thoughts on the initiation of mucositis // Oral Dis. 16 (2010):597-600. https://doi:10.1111/j.1601-0825.2010.01681.x
Al-Dasooqi N, Sonis ST, Bowen JM et al. Emerging evidence on the pathobiology of mucositis // Support Care Cancer. 2013;21:2075-2083. https://doi:10.1007/s00520-013-1810-y
Mallick S, Benson R, Rath GK. Radiation induced oral mucositis: a review of current literature on prevention and management // Eur Arch Otorhinolaryngol. 2015;273:2285-2293. https://doi:10.1007/s00405-015-3694-6
Maria OM, Eliopoulos N, Muanza T. Radiation-induced oral mucositis // Front Oncol. 2017;7:5121-5123. https://doi:10.3389/fonc.2017.00089
National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). 2018:1-147.
Lalla RV, Bowen J, Barasch A et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy // Cancer. 2014;120:1453-1461. https://doi:10.1002/cncr.28592
Kawashita Y, Hayashida S, Funahara M et al. Prophylactic bundle for radiation-induced oral mucositis in oral or oropharyneal cancer patients // J Cancer Res Ther. 2014;2:9–13 https://doi:dx.doi.org/10.14312/2052-4994.2014-2
Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients who have cancer // Dent Clin North Am. 2008;52:61–77. https://doi:10.1016/j.cden.2007.10.002
Bonomi M, Batt K. Supportive management of mucositis and metabolic derangements in head and neck cancer patients // Cancers. 2015;7:1743-1757. https://doi:10.3390/cancers7030862
Epstein JB, Epstein JD, Epstein MS et al. Oral doxepin rinse: the analgesic effect and duration of pain reduction in patients with oral mucositis due to cancer therapy // AnesthAnalg. 2006;103:465-470. https://doi:10.1213/01.ane.0000223661.60471.78
Leenstra JL, Miller RC, Qin R et al. Doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy: a Phase III, randomized, double-blind trial (NCCTG-N09C6 [Alliance]) // Jco. 2014;32:1571-1577. https://doi:10.1200/JCO.2013.53.2630
Giralt J, Tao Y, Bensadoun RJ, Lalla RV, Ozsahin EM. Mucoadhesive clonidine (Clonidine Lauriad) in the prevention of severe radiomucositis in head and neck cancer patients: a phase II randomized trial. 2015. https://doi:org/10.1200/jco.2015.33.15_suppl.6058
Nagi R, Patil DJ, Rakesh N et al. Natural agents in the management of oral mucositis in cancer patients-systematic review // J Oral Biol Craniofacial Res. 2018;8:245-254. https://doi:10.1016/j.jobcr.2017.12.003
Spielberger R, Stiff P, Bensinger W et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers // N Engl J Med. 2004;351:2590-2598. https://doi:10.1056/NEJMoa040125
Kudrimoti M, Curtis A, Azawi S et al. Dusquetide: a novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study // J Biotechnol. 2016;239:115-125. https://doi:10.1016/j.jbiotec.2016.10.010
Kudrimoti M, Curtis A, Azawi S et al. Dusquetide Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients // Biotechnol Rep. 2017;15:24-26. https://doi:10.1016/j.btre.2017.05.002
Anderson CM, Sonis ST, Lee CM et al. Phase 1b/2a trial of the superoxide dismutase mimetic GC4419 to reduce chemoradiotherapy-induced oral mucositis in patients with oral cavity or oropharyngeal carcinoma // Int J RadiatOncolBiol Phys. 2018100:427-435. https://doi:10.1016/j.ijrobp.2017.10.019
Epstein JB, Silverman S, Paggiarino DA et al. BenzydamineHCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial // Cancer. 2001;92:875-885. https://doi:10.1002/1097-0142(20010815)92:4<875::aid-cncr1396>3.0.co;2-1
Kazemian A, Kamian S, Aghili M et al. Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers: a double-blind placebo-controlled randomized clinical trial // Eur J Cancer Care (Engl). 2009;18:174-178. https://doi:10.1111/j.1365-2354.2008.00943.x
. Johnson JT, Ferretti GA, Nethery WJ et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer // N Engl J Med. 1993;329:390–395. https://doi:10.1056/NEJM199308053290603
Davies AN, Thompson J. Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy // Cochrane Database Syst Rev. 2015;10. https://doi:10.1002/14651858.CD003782.pub3
Iwabuchi H, Iwabuchi E, Uchiyama K, Fujibayashi T. Study on reducing adverse reactions to piloarpine hydrochloride -possibility of reducing sweating by adoption of multiple divided low-dose treatment // J JpnSoc Oral Mucous Membr. 2010;16:17–23.
Bamps M, Dok R, Nuyts S. Low-level laser therapy stimulates proliferation in head and neck squamous cell carcinoma cells // Front Oncol. 2018;8:253-256. https://doi:10.3389/fonc.2018.00343
Lopes NNF, Plapler H, Chavantes MC et al. Cyclooxygenase-2 and vascular endothelial growth factor expression in 5-fluorouracil-induced oral mucositis in hamsters: evaluation of two low-intensity laser protocols // Support Care Cancer. 2009;17:1409-1415. https://doi:10.1007/s00520-009-0603-9
Gautam AP, Fernandes DJ, Vidyasagar MS et al. Low level laser therapy for concurrent chemoradiotherapy induced oral mucositis in head and neck cancer patients — a triple blinded randomized controlled trial // RadiotherOncol. 2012;104:349-354. https://doi:10.1016/j.radonc.2012.06.011
Lopes NNF, Plapler H, Lalla RV et al. Effects of low-level laser therapy on collagen expression and neutrophil infiltrate in 5-fluorouracil-induced oral mucositis in hamsters // Lasers Surg Med. 2010;42:546-552. https://doi:10.1002/lsm.20920
Bjordal JM, Bensadoun R-J, Tunèr J et al. A systematic review with meta-analysis of the effect of low-level laser therapy (LLLT) in cancer therapy-induced oral mucositis // Support Care Cancer. 2011;19:1069-1077. https://doi:10.1007/s00520-011-1202-0
Reitemeier B, Reitemeier G, Schmidt A et al. Evaluation of a device for attenuation of electron release from dental restorations in a therapeutic radiation field // J ProsthetDent. 2002;87:323–327.
Kawashita Y, Hayashida S, Funahara M et al. Prophylactic bundle for radiation-induced oral mucositis in oral or oropharyneal cancer patients // J CancerResTher. 2014;2:9–13. https://doi:dx.doi.org/10.14312/2052-4994.2014-2
Sánchez Alvarez C, Nuñez Ruiz R, MoránGarcía V. Nutritional support in the patient with GI malignancy // NutrHosp. 2005;20(2):38–40. PMID: 15981849
Луфт В.М., Луфт А.В. Нутриционная поддержка онкологических больных: возможности и противоречия // Вестник интенсивной терапии. 2008;2:43–50. [Luft VM, Luft AV. Nutritional support of oncological patients: Possibilities and challenges. Vestnikintensivnoyterapii // Vestnik intensivnoy terapii. 2008;2:43–50. (In Russ.)].
Scully С., Epstein J, Sonis S. Oral mucositis: a challenging complication of radiotherapy, chemotherapy and radiochemotherapy. Part 2: diagnosis and management of mucositis // Head Neck. 2004;26(1):77–84. https://doi:10.1002/hed.10326. PMID: 14724910
Pauloski BR. Rehabilitation of dysphagia following head and neck cancer // Phys Med RehabilClin N Am. 2008;9:889–928. https://doi:10.1016/j.pmr.2008.05.010
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2021